Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2021-03-15 Regulatory Filings
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release from Tetra Bio-Pharma providing an update on the status of its New Drug Submission (NDS) application with Health Canada. It discusses regulatory review progress, expected market impact, and future plans for the drug REDUVO™. There are no financial statements, detailed financial analysis, or comprehensive report content. The document is an update on a regulatory and product development milestone rather than a financial report or detailed investor presentation. It is not a report publication announcement since it does not mention the release or availability of a report. The content fits best under a Regulatory Filings (RNS) category as it is a general regulatory announcement and company update that does not fit other specific categories like Capital/Financing Update or Legal Proceedings. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2021-03-15 English
News release - English.pdf
Regulatory Filings
2021-03-08 English
News release - English.pdf
Investor Presentation Classification · 90% confidence The document is a press release announcing that Tetra Bio-Pharma's CEO will present at the H.C. Wainwright Global Life Sciences Virtual Conference. It describes the event details, webcast availability, and company background. There is no financial data, no detailed report, no voting results, no management changes, no legal proceedings, no audit information, and no regulatory filing content. The document is essentially an investor presentation announcement or event announcement. Given the content is about a presentation event and not the presentation itself, and it is a short announcement, the best fitting category is Investor Presentation (IP).
2021-03-03 English
Material change report - English.pdf
Capital/Financing Update Classification · 95% confidence The document is titled 'FORM 51-102F3 MATERIAL CHANGE REPORT' and details a material change event dated March 2, 2021. It describes the closing of a bought-deal public offering of units, including the exercise of an over-allotment option, with specifics on the number of units sold, pricing, and use of proceeds. The document references regulatory compliance with Canadian securities laws and provides contact information for an executive officer. The content focuses on a material change announcement related to financing activity rather than a full financial report or earnings release. Given the detailed description of a financing event and the nature of the document as a material change report, the appropriate classification is Capital/Financing Update (CAP). The document length (6239 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2021-03-02 English
Other securityholders documents - English.pdf
Regulatory Filings
2021-03-02 English
News release - English.pdf
Capital/Financing Update Classification · 100% confidence The document is a press release announcing the closing of a bought deal public offering by Tetra Bio-Pharma Inc. It details the number of units sold, pricing, use of proceeds, and regulatory approvals related to the offering. There is no financial statement data, no detailed financial analysis, or report content. The document is an update on a financing activity, specifically a capital raise through a bought deal offering. This fits the category of Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the financing event, not just a brief announcement or a link to a report, so it is not a Report Publication Announcement (RPA) or Regulatory Filing (RNS).
2021-03-02 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.